Home
Finance
Bank Routing Numbers
FedWire
Stock Portfolio Generator
Technical Analysis of Stocks
Best Months to Buy or Sell Stocks
Games
Hangman - Hang 'Em High
Chess
Shuttles Game
Chemistry
Chemical Equation Balancer
Periodic Table of the Elements
Chemical Bond Polarity Calculator
Linear Algebra
Gauss-Jordan Elimination Calculator
Calculate Pivots
Factorize: A=LU
Inverse Matrix Calculator
Null Space Calculator
Column Space Calculator
Row Space Calculator
Multiply Two Matrices
AI
Genetic Algorithms
Genetic Algorithms Stock Portfolio Generator
Shuttles Game
Tic-Tac-Toe Game
Personality Profile
Checkers Game
Scripts
Scan for all machines running IIS in a domain
Extract data from a Microsoft Word document
Outlook Scripts
Excel Scripts
IT
How to Stop a DDOS Attack
Subnet Calculator
Fingerprint Web Server
Whois Lookup
InternetPeriscope
About
My Favorite Links
Resume
View My Profile on LinkedIn
View My Profile on DataCamp
View My Profile on Pluralsight
Back to Companies who have applied for FDA Drug Approval
FDA Drug Approval Applications Sponsored by SCHERING
Application Number
Drugs/Products
Application Type
Most Recent Label Available Flag
Current Patent Flag
Action Type
Chemical Type
Ther Potential
Orphan Code
003158
ORETON METHYL
New Drug Application
Approval
005292
ESTINYL
New Drug Application
Approval
005963
SODIUM SULAMYD
New Drug Application
Approval
006921
CHLOR-TRIMETON
New Drug Application
Approval
008114
PRANTAL
New Drug Application
Approval
New molecular entity (NME)
(S) Standard review drug
009766
METICORTEN
New Drug Application
Approval
New molecular entity (NME)
(P) Priority review drug
010209
METI-DERM
New Drug Application
Approval
New formulation
(S) Standard review drug
010210
METIMYD
New Drug Application
Approval
New combination
(S) Standard review drug
010255
METICORTELONE
New Drug Application
Approval
New formulation
(S) Standard review drug
010775
TRILAFON
New Drug Application
Approval
New molecular entity (NME)
(S) Standard review drug
010909
MIRADON
New Drug Application
Approval
New molecular entity (NME)
(S) Standard review drug
011213
TRILAFON
New Drug Application
Approval
New formulation
(S) Standard review drug
011294
TRILAFON
New Drug Application
Approval
New formulation
(S) Standard review drug
011361
TRILAFON
New Drug Application
Approval
New formulation
(S) Standard review drug
011557
TRILAFON
New Drug Application
Approval
New formulation
(S) Standard review drug
011814
DISOMER
New Drug Application
Approval
New molecular entity (NME)
(S) Standard review drug
012034
PERMITIL
New Drug Application
Approval
New molecular entity (NME)
(S) Standard review drug
012155
RELA
New Drug Application
Approval
New manufacturer
(S) Standard review drug
012254
TINDAL
New Drug Application
Approval
New molecular entity (NME)
(S) Standard review drug
012265
NAQUA
NAQUIVAL
New Drug Application
Approval
New molecular entity (NME)
(S) Standard review drug
012394
DISOPHROL
New Drug Application
Approval
New ester, new salt, or other noncovalent derivative; New combination
(S) Standard review drug
012419
PERMITIL
New Drug Application
Approval
New formulation
(S) Standard review drug
012470
AKRINOL
New Drug Application
Approval
New ester, new salt, or other noncovalent derivative
(S) Standard review drug
012657
CELESTONE
New Drug Application
Approval
New molecular entity (NME)
(S) Standard review drug
014713
ETRAFON 2-10
ETRAFON 2-25
ETRAFON-A
ETRAFON-FORTE
New Drug Application
Approval
New manufacturer
(S) Standard review drug
014762
CELESTONE
New Drug Application
Approval
New formulation
(S) Standard review drug
016008
PERMITIL
New Drug Application
Approval
New formulation
(S) Standard review drug
016053
BETAPAR
New Drug Application
Approval
New molecular entity (NME)
(S) Standard review drug
016322
VALISONE
New Drug Application
Approval
New ester, new salt, or other noncovalent derivative
(S) Standard review drug
016740
VALISONE
New Drug Application
Approval
New formulation
(S) Standard review drug
016932
VALISONE
New Drug Application
Approval
New formulation
(S) Standard review drug
016996
HYPERSTAT
New Drug Application
Approval
New molecular entity (NME)
(P) Priority review drug
017536
DIPROSONE
New Drug Application
Approval
New ester, new salt, or other noncovalent derivative
(S) Standard review drug
017559
PROVENTIL
New Drug Application
Approval
New molecular entity (NME)
(P) Priority review drug
017561
CELESTONE
New Drug Application
Approval
New formulation
(S) Standard review drug
017573
VANCERIL
New Drug Application
Approval
New molecular entity (NME)
(P) Priority review drug
017601
OPTIMINE
New Drug Application
Approval
New molecular entity (NME)
(S) Standard review drug
017691
DIPROSONE
New Drug Application
Approval
New formulation
(S) Standard review drug
017736
PAXIPAM
New Drug Application
Approval
New molecular entity (NME)
(S) Standard review drug
017781
DIPROSONE
New Drug Application
Approval
New formulation
(S) Standard review drug
017829
DIPROSONE
New Drug Application
Approval
New formulation
(S) Standard review drug
017853
PROVENTIL
New Drug Application
Approval
New formulation
(S) Standard review drug
018062
PROVENTIL
New Drug Application
Approval
New formulation
(S) Standard review drug
018506
TRINALIN
New Drug Application
Approval
New combination
(S) Standard review drug
018521
VANCENASE
New Drug Application
Approval
New formulation
(P) Priority review drug
018554
EULEXIN
New Drug Application
Approval
New molecular entity (NME)
(P) Priority review drug
018686
NORMODYNE
New Drug Application
Approval
New molecular entity (NME)
(P) Priority review drug
018687
NORMODYNE
New Drug Application
Approval
New formulation
(S) Standard review drug
018813
LOTRIMIN
New Drug Application
Approval
New formulation
(S) Standard review drug
019046
NORMOZIDE
New Drug Application
Approval
New combination
(S) Standard review drug
019243
PROVENTIL
New Drug Application
Approval
New formulation
(S) Standard review drug
019383
PROVENTIL
New Drug Application
Approval
New formulation
(S) Standard review drug
019408
DIPROLENE
New Drug Application
Approval
New formulation
(S) Standard review drug
019439
POTASSIUM CHLORIDE
New Drug Application
Approval
New formulation
(S) Standard review drug
019589
VANCENASE AQ
New Drug Application
Approval
New manufacturer
(S) Standard review drug
020240
RENORMAX
New Drug Application
Approval
New molecular entity (NME)
(S) Standard review drug
(V) Orphan drug
020469
VANCENASE AQ
New Drug Application
Approval
New formulation
(S) Standard review drug
020486
VANCERIL DOUBLE STRENGTH
New Drug Application
Approval
New formulation
(S) Standard review drug
020718
INTEGRILIN
New Drug Application
Approval
New molecular entity (NME)
(P) Priority review drug
021297
CLARINEX
New Drug Application
Approval
New indication
(S) Standard review drug
021363
CLARINEX
New Drug Application
Approval
New indication
(S) Standard review drug
021546
REBETOL
New Drug Application
Approval
New formulation
(P) Priority review drug
(V) Orphan drug
021563
CLARINEX
New Drug Application
Approval
New formulation
(P) Priority review drug
022003
NOXAFIL
New Drug Application
Approval
New molecular entity (NME)
(P) Priority review drug
022027
NOXAFIL
New Drug Application
Approval
New indication
050039
GARAMYCIN
New Drug Application
Approval
050425
GARAMYCIN
New Drug Application
Approval
050505
GARAMYCIN
New Drug Application
Approval
New formulation
(S) Standard review drug
050544
NETROMYCIN
New Drug Application
Approval
New molecular entity (NME)
(S) Standard review drug
060462
GARAMYCIN
Abbreviated New Drug Application
Approval
060463
GARAMYCIN
Abbreviated New Drug Application
Approval
061716
GARAMYCIN
Abbreviated New Drug Application
Approval
061739
GARAMYCIN
Abbreviated New Drug Application
Approval
061816
OTOBIONE
Abbreviated New Drug Application
Approval
062302
OTOBIOTIC
Abbreviated New Drug Application
Approval
070120
PROPRANOLOL HYDROCHLORIDE
Abbreviated New Drug Application
Approval
070121
PROPRANOLOL HYDROCHLORIDE
Abbreviated New Drug Application
Approval
070122
PROPRANOLOL HYDROCHLORIDE
Abbreviated New Drug Application
Approval
070123
PROPRANOLOL HYDROCHLORIDE
Abbreviated New Drug Application
Approval
070124
PROPRANOLOL HYDROCHLORIDE
Abbreviated New Drug Application
Approval
070598
METOCLOPRAMIDE HYDROCHLORIDE
Abbreviated New Drug Application
Approval
080281
ORETON
Abbreviated New Drug Application
Approval
080381
TREMIN
Abbreviated New Drug Application
Approval
083834
METRETON
Abbreviated New Drug Application
Approval
085222
QUINORA
Abbreviated New Drug Application
Approval
085328
THEO-DUR
Abbreviated New Drug Application
Approval
086835
POLARAMINE
Abbreviated New Drug Application
Approval
086837
POLARAMINE
Abbreviated New Drug Application
Approval
086998
THEO-DUR
Abbreviated New Drug Application
Approval
087010
THEOVENT
Abbreviated New Drug Application
Approval
087910
THEOVENT
Abbreviated New Drug Application
Approval
087995
THEO-DUR
Abbreviated New Drug Application
Approval
088015
THEO-DUR
Abbreviated New Drug Application
Approval
088016
THEO-DUR
Abbreviated New Drug Application
Approval
088022
THEO-DUR
Abbreviated New Drug Application
Approval
089131
THEO-DUR
Abbreviated New Drug Application
Approval
089822
UNI-DUR
Abbreviated New Drug Application
Approval
089823
UNI-DUR
Abbreviated New Drug Application
Approval
103132
INTRON A
Biologic License Application
Approval
103949
PEGINTRON
SYLATRON
Biologic License Application
Approval
125196
PEGINTRON/REBETOL COMBO PACK
Biologic License Application
Approval
Back to Companies who have applied for FDA Drug Approval